GlassScriptPhysician profile
Colton Parker
NPI 1497416903
$3,546.97
in general payments reported to CMS, 2019-2025
25 companies · $780 in 2025
The $780 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $803 · 2023: $863 · 2024: $1,101 · 2025: $780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,744.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.04 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $517.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $329.73 | 2022-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $245.41 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $203.19 | 2022-2023 | Xarelto |
| Lilly USA, LLC | $188.33 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $173.28 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $161.77 | 2023-2024 | Nexletol, Nexlizet |
| Bayer Healthcare Pharmaceuticals INC. | $152.93 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $143.93 | 2022-2023 | |
| Pfizer INC. | $131.62 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $130.89 | 2023 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $121.94 | 2022-2025 | Zoryve, Livalo |
| Abbvie INC. | $101.43 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $49.67 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $41.59 | 2024 | Fisher & Paykel Healthcare |
| Lundbeck LLC | $32.96 | 2023-2024 | Rexulti |
| Eisai INC. | $31.14 | 2025 | |
| Ibsa Pharma INC. | $22.27 | 2024 | Tirosint, Licart |
| Amarin Pharma, INC. | $21.40 | 2022 | |
| Sumitomo Pharma America, INC. | $18.93 | 2023 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $18.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2024 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $14.80 | 2025 | Onpattro |
| Merck Sharp & Dohme LLC | $13.57 | 2025 | Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colton Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.